JAMA vs The Lancet: Which Journal Should You Submit To?

The Lancet has the higher impact factor: 88.5 vs. 55.0 (JIF 2024 JCR data). That's a significant gap—The Lancet ranks #1 in medicine globally. JAMA ranks #4, still exceptional but a step below. For hiring committees and grant reviewers, publishing in The Lancet carries more weight, especially internationally. In the US clinical world, JAMA is equally prestigious.

Both are career-defining publications. If your work is strong enough for either, aim for The Lancet first, but don't overlook JAMA as a legitimate primary target.

The Lancet emphasizes global health, major clinical trials, and research with broad international relevance. The journal welcomes epidemiological studies, policy analysis, and public health research alongside clinical discovery. Articles often have a "story" about disease burden or population impact.

JAMA has a stronger focus on clinical medicine, diagnostic accuracy, and patient outcomes. It publishes landmark trials, but also high-quality original research on disease mechanisms, prevention, and treatment. JAMA has a more US-clinical tone, though it's increasingly international.

In practice: if your trial involves multiple countries and addresses a global health concern, The Lancet may be ideal. If it's a rigorous US-based clinical trial or mechanistic study with clear patient relevance, JAMA is competitive.

The Lancet editors look for novelty with scale—findings that matter beyond a single institution or population. The framing emphasizes "what does this mean for global medicine?" Reviewers are strict about significance and generalizability.

JAMA editors prioritize clinical utility and methodological rigor. They ask: "Will this change how clinicians practice?" The framing is pragmatic—how does this finding apply to everyday medicine? JAMA accepts excellent studies that may be narrower in scope than The Lancet would require.

Practical difference: A single-center trial showing a new treatment benefit might be rejected by The Lancet as too narrow but could succeed at JAMA if the science is sound and the treatment is novel.

Both are highly selective. JAMA accepts roughly 1% of submissions; The Lancet accepts about 1-2%. The competition is fierce. Even exceptional papers have slim odds. This isn't reason to avoid them—but manage expectations accordingly.

Both are slow. Expect 3-6 months to first decision. The Lancet can be slightly faster on desk rejections (2-3 weeks). JAMA sometimes takes longer in peer review. Neither is a quick publication path. Plan accordingly for your timeline.

If your work fits equally well in both, consider:

If you must choose one, submit to The Lancet first. If rejected, JAMA is your next logical target.

If The Lancet rejects your paper citing narrow scope or insufficient novelty, JAMA is an excellent second option—the bar for clinical utility is lower. If JAMA rejects on methodological grounds, The Lancet won't be more receptive. Consider whether the critique is about your research or about fit.

Most strong papers are rejected at both journals. It's normal. Even impeccable trials often cycle through 3-4 journals before finding a home. Submit where you think the best fit is, handle rejection professionally, and move to your next target—whether that's a specialty journal, Nature Medicine, or a top-tier regional publication.